100¦~12¤ë¸¹ ¹D ªk ªk °T (236)

DEEP & FAR

 

 

¥­¦æ¿é¤Jªñªp

 

§d¥©¬Â µ{§Ç¤@²Õ°Æ¥D¥ô

¡D¬Fªv¤j¾Çªk«ß¾Ç¨t¾Ç¤h

 

 

 

 

¤W¶Dªk°|»{¦PÁp¦W°Ó¼Ð(co-branding)¥i¯à·l®`­ì°Ó¼Ð«HÅA¡A¦ý©ó¦¹®×·í¤¤¡A¨ÃµLÃÒ¾Ú¥iÃÒ©ú·l®`¡C¯S§Oªº¬O¡A¨Ã¨S¦³ÃÒ¾ÚÅã¥Ü±Ä¨úÁp¦W°Ó¼Ð¤è¦¡±N·t¥Ü©Î¨Ï¤HÁp·Q¶i¤f°Ó»P»s³yªÌ¦³¬YºØµ{«×¤WªºÃöÁp¦Ó¾É­P¹êÅé²V²c¡F¥ç¨S¦³ÃÒ¾ÚÅã¥Ü¥h°£°Ó¼Ð(de-branding)·|¾É­P¥ô¦ó·l®`¡C¦b¤Ï¹ï¥h°£°Ó¼Ð®É¡Aªk©x«h¯S§O»é¥¸¦¹ºØ¬Ýªk¡A¥L´£¤Î¡u§Ú¤£»{¬°°Ó¼Ð©Ò¦³¤H¦³¥ô¦óÅv§Q­n¨D«áÄò¸g¾P°Ó©ó¨ä°Ó«~¤W«O¯d­ì¥»°Ó¼Ð¡v¡C

µM¦Ó¡A¾¨ºÞ¦³¦¹ÄÄ©ú¡A¦ý¼Ú¬w¤j³¡¤Àªºªk°|°w¹ï³o¨ÇijÃD¤Î¦ó®É¸Ó¹ê°È¥i³Qµø¬°«ÈÆ[¥²­n¡A¤´±Ä¨ú»P¥»§P¨M¤£¦Pªº§@ªk¡C¦]¦¹¡A¤W¶Dªk°|ªí¥Ü±N¶i¤@¨B±N°ÝÃD´£¥æ¼Ú¬wªk°|¡A¥H´M¨D§ó²M·¡ªº«ü¾É¤è°w©ó¦A¼ÐÅҩέ«·s¥]¸Ë¤W¡C

Glaxo Group Limited v. Dowelhurst Ltd.

¥»®×¨Ò¤D¤@«h§Y¨Mµô§P(summary judgment)®×¥ó¡A¨ä¤¤­ì§i¥H§é¦©»ù(discounted rate)³c°âÃÄ«~¤©¼Ú¬w¸gÀÙ°Ï(EEA)¡A¨ä½Ì¸Ñ¬O¥L­Ì¥u¯à©ó«D¬w§@¬°¤H¹D±Ï´©¡C¨Æ¹ê¤W¡A³o¨ÇÃÄ«~¬O½æµ¹¤@®a·ç¤h¤½¥q¡A¦A¥Ñ¨äÂà°â¥­¦æ¿é¤J¶i¤f°Ó¡CÀH«á«o¦b­^°ê¥«³õµo²{³o¨ÇÃÄ«~ªºÂܼv¡A¦Ó­ì§i¦b¦¹¦a±±§i¶i¤f°Ó«I®`¨ä°Ó¼Ð¡C

®Ú¾Ú¦b²Ä¤C±ø¡A¦pªG­ì§i³Qµo²{¤w¸g³c°â¦Ó¨Ï³o¨Ç°Ó«~©ó¼Ú¬w¸gÀÙ°Ï°ê®a¥«³õ¤W¥«¡A«h¨äÅv§Q¤w¸g¯ÓºÉ¡C­ì§i¥D±i¨ä¨Ã¥¼³o¼Ë°µ¡A¦]¬°§Y¨Ï³oµ§¶R½æ¦b¼Ú¬w¸gÀٰϤº¬°¤§¡A¤]¤£§Æ±æ³o¨Ç°Ó«~¦b¸Ó»â°ì¤¤³c°â¡C²Ä¤@¦ì¶R¤è¨M©w¡u³c°â¡vÃÄ«~¦Ó¤£¬O¡u¨Ï¥Î¡v©ó«D¬w¡A­ì§i»{¬°¦¹¦æ¬°¬O¡u´ÛÄF¡v¡AÁöµM¨Ã¨S¦³ÃÒ¾ÚÅã¥Ü¤w¹H¤Ï¥ô¦ó«´¬ù¡C(«ÝÄò...)